Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Recurrence 3Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Tuberous Sclerosis 1Solid Tumors 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 8ibrutinib 5fludarabine phosphate 5fludarabine 5pirtobrutinib 4Mesna 4obinutuzumab 3acalabrutinib 3Mycophenolic Acid 3Melphalan 3venetoclax 2Whole-Body Irradiation 2Tacrolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Busulfan 2Bone Marrow Transplantation 2ARQ531 2ricolinostat 1idelalisib 1idecabtagene vicleucel 1Vincristine 1Stem Cell Transplantation 1Rabeprazole 1Prednisone 1Leukapheresis 1Itraconazole 1Filgrastim 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Itraconazole × 1 year × Clear all
NCT06787131 2025-12-05

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

Lomond Therapeutics Holdings, Inc.

Phase 1 Completed
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡